换一批
换一批Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
第一作者：
M D,Pegram
第一单位：
Department of Medical Oncology, The University of California at Los Angeles, USA. mpegram@ucla.edu
作者：
主题词
成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);乳腺肿瘤(Breast Neoplasms);顺铂(Cisplatin);疾病恶化(Disease Progression);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);基因, erbB-2(Genes, erbB-2);人类(Humans);中年人(Middle Aged)
DOI
10.1200/JCO.1998.16.8.2659
PMID
9704716
发布时间
2022-04-08
- 浏览226
Journal of clinical oncology
2659-71页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
